Company Filing History:
Years Active: 2021-2023
Title: Iwan Beuvink: Innovator in Monoclonal Antibody Research
Introduction
Iwan Beuvink is a prominent inventor based in Basel, Switzerland. He has made significant contributions to the field of immunology through his innovative research and development of humanized monoclonal antibodies. With a total of 2 patents, Beuvink is recognized for his work in creating antibodies that target human interleukin-2.
Latest Patents
Beuvink's latest patents include "Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof." This invention focuses on antibodies that bind to human interleukin-2 (hIL-2). More specifically, it involves humanized antibodies that target a particular epitope of hIL-2. When these antibodies bind to this epitope, they exhibit a unique capability of inhibiting the binding of hIL-2 to CD25.
Career Highlights
Iwan Beuvink is affiliated with Universität Zürich, where he continues to advance his research in immunology. His work has garnered attention for its potential applications in therapeutic treatments and immune response modulation.
Collaborations
Beuvink collaborates with notable colleagues, including Natalia Arenas-Ramirez and Onur Boyman. Their combined expertise contributes to the innovative research environment at Universität Zürich.
Conclusion
Iwan Beuvink's contributions to the field of monoclonal antibodies highlight his role as a key innovator in immunology. His patents reflect a commitment to advancing medical science and improving therapeutic options for patients.